USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Alexion Pharmaceuticals, Inc.
Address:
352 Knotter Drive
Cheshire, CT 06410
Phone:
(203) 271-8221
URL:
N/A
EIN:
133648318
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,035,396.00 6
SBIR Phase II $734,816.00 1

Award List:

Somatic Cell Gene Therapy for Hemophilia B

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$74,636.00
Agency:
HHS
Principal Investigator:
Scott Kennedy
Abstract:
Blood coagulation factor IX is absent or deficient in hemophilia B patients. Current therapy, thetransfusion of human whole blood components, is effective, but it is not prophylactic or free of risk.Our long term objective is the development of a somatic cell gene therapy for hemophilia B.… More

Complement Activation and the Platelet Storage Le

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Scott Rollins
Abstract:
N/a

Complement Activation and the Platelet Storage Le

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$734,816.00
Agency:
HHS
Principal Investigator:
Scott Rollins
Abstract:
We will systematically examine whether complement activation plays a significant role in theplatelet storage lesion (PSL). The goals of the project are four-fold: (1) to assess the etiology of PSL bydepleting complement factor 8 from platelet storage plasma; (2) determine if monoclonal… More

Generation of Complement Resistant Retroviral Vectors

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Russell Rother
Abstract:
The inactivation of retroviral vectors derived from murine cells in human serum represents a formidmany potential applications of in vivo retroviral-mediated gene therapy. We have recently demonstratof amphotropic retroviral vector particles in human serum is primarily mediated by complement… More

COMPLEMENT ACTIVATION AND MYOCARDIAL INFARCTION

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$93,760.00
Agency:
HHS
Principal Investigator:
Rollins, scott a
Abstract:
Coronary artery disease is associated with extensive morbidity and mortality as well as substantial financial cost. An estimated 11.2 million people in the USA have coronary artery disease that leads to approximately 1.5 million acute myocardial infarctions (AMI) annually. The mechanism by which… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Yi Wang
Abstract:
N/a

Nebulizing Eculizumab for intrapulmonary C5 inhibition

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$592,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The complement component C5 is common to all three pathways of complement activation. Its involvement in the pathogenesis of asthma is controversial. We have recently shown that the intrapulmonary activation of C5 is critical in animal models of asthma… More